ABUS for Early-stage Breast Cancer
Launched by SAMSUNG MEDICAL CENTER · Oct 22, 2020
Trial Information
Current as of May 11, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Patients with early-stage breast cancer (clinical Tis, T1- T2 cancers are suspected on mammography at the time of diagnosis), without palpable nodes at physical examination (N0)
- • Patients who schedule to undergo surgery and sentinel lymph node biopsy
- • Patient's age between 25-69 years
- • Patients who voluntarily agree to participate in this study
- Exclusion Criteria:
- • A history of previously treated breast cancers
- • Patients who undergo excision biopsy for diagnosed breast cancer
- • Pregnant or lactating women
- • Patients who have breast implants
About Samsung Medical Center
Samsung Medical Center (SMC) is a leading healthcare institution in South Korea, renowned for its commitment to advancing medical research and innovation. As a prominent clinical trial sponsor, SMC integrates cutting-edge technology and expert clinical practices to conduct rigorous studies aimed at improving patient outcomes. The center is dedicated to fostering collaborations with global research entities and adhering to the highest ethical standards, ensuring the integrity and reliability of its clinical trials. With a focus on diverse therapeutic areas, SMC plays a pivotal role in translating scientific discoveries into effective treatments, ultimately enhancing the quality of healthcare worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Seoul, Seoul Teukbyeolsi [Seoul], Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Patients applied
Trial Officials
Ji Soo Choi, MD,PhD
Principal Investigator
Samsung Medical Center, Department of Radiology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials